KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ClearPoint Neuro (CLPT) EBT (2018 - 2026)

ClearPoint Neuro's EBT history spans 13 years, with the latest figure at -$7.8 million for Q4 2025.

  • On a quarterly basis, EBT fell 43.63% to -$7.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$25.5 million, a 34.83% decrease, with the full-year FY2025 number at -$25.5 million, down 34.83% from a year prior.
  • EBT hit -$7.8 million in Q4 2025 for ClearPoint Neuro, down from -$5.9 million in the prior quarter.
  • Over the last five years, EBT for CLPT hit a ceiling of -$2.5 million in Q1 2021 and a floor of -$7.8 million in Q4 2025.
  • Historically, EBT has averaged -$4.9 million across 5 years, with a median of -$4.6 million in 2022.
  • Biggest five-year swings in EBT: tumbled 174.41% in 2021 and later surged 38.4% in 2024.
  • Tracing CLPT's EBT over 5 years: stood at -$4.1 million in 2021, then fell by 7.79% to -$4.5 million in 2022, then decreased by 5.3% to -$4.7 million in 2023, then fell by 15.13% to -$5.4 million in 2024, then tumbled by 43.63% to -$7.8 million in 2025.
  • Business Quant data shows EBT for CLPT at -$7.8 million in Q4 2025, -$5.9 million in Q3 2025, and -$5.8 million in Q2 2025.